Ligand Pharmaceuticals (NASDAQ: LGND)
Ligand Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ligand Pharmaceuticals Company Info
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
News & Analysis
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
3 Signs the Ligand Short Squeeze Is Over
The Reddit crowd wasn't the only reason short-sellers got burned betting against this pharmaceutical company.
Forget Gamestop! This Highly Shorted Stock Is A Strong Buy Now
The unusual biotech could be a bitter pill for short sellers to swallow.
Short-Sellers Have These 3 ETFs in Their Sights
Should investors watch for a squeeze?
Ligand Trounces Q2 Estimates by Helping Companies Make COVID-19 Drug Remdesivir
The company posted strong revenue and earnings growth in Q2 and upped its full-year outlook.
3 Top Biotech Stocks to Buy in August
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
5 Top Biotech Stocks to Buy in 2019
Looking for potential winning biotech stocks? These five check off all the boxes for investors.
Here's Why Ligand Pharmaceuticals Is Having a Bad Day
Investors are not impressed with the company's plan to finance an acquisition spree.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.